IQ Case Studies
Our case studies describe initiatives undertaken by IQ's Working Groups in detail, including the challenges they set out to address, their approaches, and the results and impact of their work.
Assessing the Value of Nonclinical Testing to Enable Safe Entry to First in Human Clinical Trials
Before a new drug can be evaluated in human clinical trials, study sponsors are required to conduct animal toxicology studies to understand potential toxic effects of the drug and help establish a starting clinical dose. This testing, which is required by regulatory agencies, assumes that the animal model and toxicology studies will identify possible human hazards. However, there is active debate in the literature about the utility of animal testing in drug development and there is limited published data that scientifically addresses correlations between toxicities observed in animal models to adverse events in humans. The IQ Nonclinical to Clinical Translational Safety Working Group addressed this gap in information by collecting and analyzing how animal toxicity data predicted safety issues in humans in studies.
Advancing Global Collaboration in Pediatric Formulation Development
The use of pharmaceuticals for treatment of pediatric patients is ubiquitous in clinical practice. In many instances, clinicians, pharmacists, and parents treat children with dose forms and products designed for and tested in adults. This practice can lead to incorrect dosing, poor acceptance, and therapeutic failure or adverse events. Enhanced awareness of these issues, pediatric patients’ needs, and evolving regulatory expectations has generated a focus on development of age-appropriate pediatric drug products for clinical and commercial use. Understanding the best product presentations for a diverse pediatric population as well as how to administer these products and assess their acceptability are areas of key importance and rapid innovation for regulators, academics, and the pharmaceutical industry. The Drug Product Pediatric Working Group was created to address the above challenges and catalyze advancement of science and technologies for age-appropriate formulation development.
Inspiring Sustainable Drug Manufacturing with a Smart Goal Metric
Green and sustainable chemistry is critical for balancing the long-term sustainability of business, society, and the environment. It stimulates scientific innovation, reduces environmental footprint, lowers development and manufacturing costs, and can therefore contribute to the greater affordability of drugs for patients. However, the full potential of sustainable drug manufacturing has been inhibited by the absence of harmonized green chemistry metrics, inconsistent starting points for analysis, and the neglected complexities of the structurally diverse drugs and their manufacturing processes. The IQ Consortium’s Green Chemistry Working Group, the ACS Green Chemistry Institute Pharmaceutical Roundtable, and Professor Roger Sheldon joined efforts to create a green chemistry metric that could catalyze innovative green process chemistry, and create a platform to reward the greenest manufacturing process.